Researchers from Xinhua Hospital have published data from a study that aimed to assess the role of CEBPG, an important regulator of tumor development, in the progression of ovarian cancer (OC).
Sanford-Burnham Medical Research Institute has disclosed baculoviral IAP repeat-containing protein 7 (BIRC7; ML-IAP) inhibitors reported to be useful for the treatment of cancer.
Exact Sciences Corp.’s long-term analysis of results from the Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A) study found that all patients diagnosed and treated for stage I or II cancers identified through its blood-based multi-cancer early detection (MCED) test remained cancer-free more than four years after diagnosis. Half of all the participants with cancer detected remained alive at four years, notable because most of the detected cancers had no recommended screening tests or standards. The results will be presented at the American Society of Clinical Oncology meeting June 2-6.
Acerand Therapeutics (Hong Kong) Ltd. has identified tetrahydrofuran-containing polycyclic derivatives and their pharmaceutically acceptable salts reported to be useful for the treatment of ovarian cancer.
Imaginab Inc. has selected and advanced into IND-enabling studies IAB-56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3-targeting program, IAB-57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later this year.
Immunogen Inc. scored a major win in top-line data from the confirmatory phase III trial called Mirasol evaluating the approved antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx, “mirv”) vs. chemotherapy in patients with folate receptor alpha-positive platinum-resistant ovarian cancer (PROC). The victory led shares of the Waltham, Mass.-based firm to close May 3 at $12.26, a rise of $7.06, or 135%.
Previous studies have shown that ovarian cancer (OC) has strong tumor heterogeneity, resulting in high recurrence and metastasis rates. In recently published work, researchers from Capital Medical University (CMU) applied single-cell transcriptomics to identify metastasis-associated cell clusters and key genes involved in OC metastasis.
Cadherin 6 (CDH6) is a transmembrane protein with high expression during embryonic kidney development, with very limited expression in adult tissues but overexpressed in several malignancies such as ovarian or renal cancer, and it is tied disease progression and poor prognosis. This pattern of expression makes it an attractive target for antibody-drug conjugate (ADC) development.
